Guardian Pharmacy Q4 Revenue Beats Estimates, 2026 EBITDA Outlook Raised by Up to 5%
Summary
Guardian Pharmacy Services reported robust Q4 results, with revenue climbing 17% year-over-year to $397.6 million, exceeding analyst consensus. The company also significantly increased its 2026 Adjusted EBITDA outlook to a range of $120 million-$124 million, up from $115 million-$118 million, representing a material boost of approximately 4-5%. This strong performance was fueled by 12% organic revenue growth, an increase in residents served, and improved operational efficiencies. The upward revision in guidance signals a more optimistic profitability trajectory, which is a clear positive catalyst for the stock. Investors will monitor the company's ability to sustain organic growth and further enhance operational leverage.
At the time of this announcement, GRDN was trading at $33.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.37 to $37.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.